Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
ONB$25.02-0.02(-0.06%)Old National Chairman and CEO Jim Ryan Named Chair-Elect of the American Bankers Association[2:07:00 PM ET]BCRD$5.530.00(0.00%)BlueOne Technologies Announces Enhance Global Remittance Platform[2:04:41 PM ET]CWK$12.14+0.24(+2.02%)Cushman & Wakefield Arranges $130 Million Sale of Seasons of Traverse Mountain in Lehi, Utah[2:01:00 PM ET]CTAS$214.12-11.81(-5.23%)Cintas Corporation Announces Quarterly Cash Dividend[2:00:00 PM ET]QNBC$46.45+0.45(+0.98%)QNB Corp. Reports Third Quarter 2026 Results[1:59:23 PM ET]CNXC$31.26-0.75(-2.36%)Concentrix Breaks the Language Barrier with Live Voice Translation[1:55:00 PM ET]CEG$258.61+6.13(+2.43%)Constellation Secures Conditional DOE Loan Commitment of up to $5 Billion to Expand Nuclear Output[1:35:00 PM ET]TXTM$0.01+0.00(+4.76%)Canouse Announces Unsatisfied Federal Judgment Against Protext Mobility, Inc. (OTC: TXTM)[1:35:00 PM ET]ARAI$0.11-0.00(-1.70%)Arrive AI Installs First Arrive Point(TM) Residential Unit[1:23:00 PM ET]

IBRX · NASDAQ

ImmunityBio, Inc.

$8.58 +0.77 (+9.86%)

Company overview

ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents in Phase II or III clinical trials for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens such as SARS-CoV-2 and HIV. It has collaboration agreements with the National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$9.1B
Employees
671
Headquarters
San Diego, CA
Website
immunitybio.com
CEO
Richard Gerald Adcock
Listed
July 28, 2015
P/E
-10.06
Dividend yield
0.00%

Company financials

Revenue
$141M
Gross profit
$132M
Operating income
-$261M
EBITDA
-$192M
Net income
-$855M
EPS
-$0.85
Total assets
$647M
Total debt
$1.1B
Gross margin
93.79%
Net margin
-606.15%
Earnings yield
-9.94%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

Showing FY 2025

Price chart

6.487.618.739.8510.98
IBRX 1D NASDAQ O8.23H8.28L7.75C7.81-0.41 (-4.99%)Vol11.05M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
IBRXImmunityBio, Inc. Legal Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ImmunityBio, Inc. (IBRX) and Encourages Shareholders to Learn More About the Investigation ACCESS Newswire
IBRXImmunityBio, Inc. Legal Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ImmunityBio, Inc. (IBRX) And Encourages Shareholders to Reach Out ACCESS Newswire
IBRXImmunityBio, Inc. Stock news Is HeartSciences Inc. (HSCS) Stock Outpacing Its Medical Peers This Year? Zacks Investment Research
IBRXImmunityBio, Inc. Legal Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ImmunityBio, Inc. (IBRX) And Encourages Shareholders to Learn More About the Investigation ACCESS Newswire
IBRXImmunityBio, Inc. Stock news ImmunityBio Study Shows Long-Term Success for Bladder Cancer Treatment Benzinga
IBRXImmunityBio, Inc. Legal Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ImmunityBio, Inc. (IBRX) and Encourages Investors to Learn More About the Investigation ACCESS Newswire
IBRXImmunityBio, Inc. Press release ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors Business Wire
IBRXImmunityBio, Inc. Stock news FDA Expands ImmunityBio's Anktiva Label in Bladder Cancer Zacks Investment Research
IBRXImmunityBio, Inc. Legal ImmunityBio, Inc. (IBRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation ACCESS Newswire
IBRXImmunityBio, Inc. Stock news ImmunityBio Stock Climbs Thursday: What's Going On? Benzinga
IBRXImmunityBio, Inc. Press release FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease Business Wire
IBRXImmunityBio, Inc. Press release ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium Business Wire
IBRXImmunityBio, Inc. Stock news ImmunityBio, Inc. (NASDAQ:IBRX) Receives Average Recommendation of “Moderate Buy” from Brokerages Defense World
IBRXImmunityBio, Inc. Stock news ImmunityBio Stock Jumps: What's Going On? Benzinga
IBRXImmunityBio, Inc. Press release These High-Voltage Stocks Are Suddenly Impossible to Ignore GlobeNewswire
IBRXImmunityBio, Inc. Stock news ImmunityBio (IBRX) Moves 7.0% Higher: Will This Strength Last? Zacks Investment Research
IBRXImmunityBio, Inc. Stock news ImmunityBio, Inc. (NASDAQ:IBRX) Receives $14.20 Consensus Target Price from Brokerages Defense World
IBRXImmunityBio, Inc. Press release PDS Biotech Announces Initial Closing of up to $22.3 GlobeNewswire
IBRXImmunityBio, Inc. Stock news Why Is ImmunityBio (IBRX) Up 9.7% Since Last Earnings Report? Zacks Investment Research
IBRXImmunityBio, Inc. Stock news ImmunityBio: None Of The Moonshots Is Priced In Seeking Alpha
See more
FAQ

Questions about ImmunityBio, Inc.

What does ImmunityBio, Inc. do?
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents in Phase II or III clinical trials for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens such as SARS-CoV-2 and HIV. It has collaboration agreements with the National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co.
What is IBRX's market cap?
ImmunityBio, Inc. (IBRX) is a listed stock with a live quote. The latest market cap on this page is $9.1B.
Where is ImmunityBio, Inc. headquartered?
ImmunityBio, Inc. is headquartered in San Diego, CA.
How do I get IBRX news from the API?
Call GET /v1/news?tickers=IBRX. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does IBRX news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for IBRX, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the IBRX price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs